Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

56.28 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bristol-Myers Squibb

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Bristol Myers Squibb Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma
From Bristol Myers Squibb
Via Business Wire
Four-Year Data from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
From Bristol Myers Squibb
Via Business Wire
Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy Demonstrates Durable Overall Survival vs. Chemotherapy at Two Years in First-Line Non-Small Cell Lung Cancer in Phase 3 CheckMate -9LA Trial
From Bristol Myers Squibb
Via Business Wire
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
From Bristol-Myers Squibb
Via Business Wire
Bristol Myers Squibb to Take Part in UBS Global Healthcare Virtual Conference
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy at American College of Cardiology’s 70th Annual Scientific Session
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology’s 70th Annual Scientific Session
From Bristol Myers Squibb
Via Business Wire
Biotechs Zero in on Growing Ovarian Cancer Market as Pivotal Trials Advance Through Regulatory Agencies
Via FinancialNewsMedia
Topics Death
Exposures Death
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Reports First Quarter Financial Results for 2021
From Bristol Myers Squibb
Via Business Wire
A Growing Market For Rare Disease Treatments Opens Up New Opportunities
Via FinancialNewsMedia
Bristol Myers Squibb to Take Part in the 7th Annual Truist Life Sciences Summit
From Bristol Myers Squibb
Via Business Wire
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Bristol-Myers Squibb Company’s Directors and Officers for Breach of Fiduciary Duties – BMY
From Scott+Scott Attorneys at Law LLP
Via Business Wire
Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
From Bristol Myers Squibb
Via Business Wire
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma....
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
From Bristol Myers Squibb
Via Business Wire
CORRECTING and REPLACING Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal...
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.